caption
stringlengths 0
3.92k
| molecule
stringlengths 1
914
| properties
sequencelengths 1
113
| additional_data
dict |
|---|---|---|---|
It belongs to the anti hypertensive class of molecules. | CC(=O)CC(=O)OCCOc1ccccc1CCOC1CCCCO1 | [
"anti hypertensive"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure that impacts barth syndrome and aging. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts tangier disease, non-alcoholic fatty liver disease, and diabetic heart disease. | CC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C | [
"Apoptosis",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Aging",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti hypertensive agent, a heart failure treatment, a cardiovascular treatment, and anti hypertensive. | CNc1cc(F)ccc1C(=O)OC(C)(C)C | [
"anti hypertensive agent",
"anti hypertensive",
"heart failure treatment",
"cardiovascular treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, fat storage, nutrient that impacts cardiovascular disease, pancreatitis, and metabolic syndrome. The molecule is a membrane stabilizer that impacts both obesity and cancer. The molecule is a inflammatory and a energy source, it impacts atherosclerosis, and is thyroxine treatment. | CC(C)CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Energy storage",
"Cardiovascular disease",
"Fat storage",
"nutrient",
"Pancreatitis",
"Metabolic syndrome",
"Obesity",
"Membrane stabilizer",
"Cancer",
"Atherosclerosis",
"Thyroxine treatment",
"inflammatory",
"Energy source"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the organic electronic device class of molecules. | C1=Cc2ccc(-c3nc(-c4ccccc4)cc(-c4ccc(-c5cccnc5)cc4)n3)cc2C2(c3ccccc31)c1ccccc1-c1c2c2ccccc2c2ccccc12 | [
"organic electronic device"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts diabetic heart disease, tangier disease, and aging. The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure that impacts barth syndrome and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Apoptosis",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation that impacts barth syndrome, aging, tangier disease, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Barth syndrome",
"Aging",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the cancer treatment class of molecules. | Cc1ccc(Nc2ccc(C(F)(F)F)cc2)c(-c2nnn(CCO)n2)c1 | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation that impacts tangier disease, barth syndrome, aging, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease. | CC(C)CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | [
"Tangier disease",
"Barth syndrome",
"Aging",
"Diabetic heart disease",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts alzheimer's disease, parkinson's disease, diabetes mellitus type 2, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCC=CO[C@H](COC(=O)CCC/C=C\C[C@H]1C=CC(=O)[C@@H]1/C=C/[C@@H](O)CCCCC)COP(=O)(O)OCCN | [
"Alzheimer's Disease",
"nutrient",
"Parkinson's disease",
"Diabetes mellitus type 2",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts aging, tangier disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, stabilizing cytochrome oxidase that impacts diabetic heart disease and non-alcoholic fatty liver disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Aging",
"Tangier disease",
"Barth syndrome",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, apoptosis, stabilizing mitochondrial structure that impacts tangier disease and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Barth syndrome",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Apoptosis",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source and fat storage, affecting cancer, and impacting metabolic syndrome, atherosclerosis, and cardiovascular disease. The molecule is a inflammatory that impacts both obesity and pancreatitis. The molecule is a thyroxine treatment, energy storage, membrane stabilizer, nutrient. | CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Metabolic syndrome",
"Atherosclerosis",
"Cardiovascular disease",
"Energy source",
"Fat storage",
"Cancer",
"Obesity",
"Pancreatitis",
"inflammatory",
"Thyroxine treatment",
"Energy storage",
"Membrane stabilizer",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a immunomodulator and belongs to the cancer treatment class of molecules. | CC(=O)NCCNCc1ccc(OCc2cccc(-c3ccccc3)c2C)cc1OCc1ccccc1CO | [
"cancer treatment",
"immunomodulator"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts barth syndrome, diabetic heart disease, and aging. | CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts non-alcoholic fatty liver disease, diabetes mellitus type 2, parkinson's disease, and alzheimer's disease. | CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OCCN | [
"nutrient",
"Non-alcoholic fatty liver disease",
"Diabetes mellitus type 2",
"Parkinson's disease",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a gsk3 inhibitor and belongs to both the diabetes treatment and alzheimer's treatment classes of molecules. | COc1cccc(OC)c1C(=O)c1sc(Nc2ccccc2)nc1N | [
"diabetes treatment",
"alzheimer's treatment",
"gsk3 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a surfactant, impacting both non-alcoholic fatty liver disease and tangier disease. The molecule is a energy source, proton trap for oxidative phosphorylation, membrane stabilizer, cholesterol translocation, energy storage. The molecule is a nutritional supplement and a food additive, it impacts aging, and is smooth. The molecule is a emulsifier, apoptosis, stabilizing mitochondrial structure that impacts barth syndrome and diabetic heart disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"surfactant",
"Energy source",
"Proton trap for oxidative phosphorylation",
"Membrane stabilizer",
"Cholesterol translocation",
"Energy storage",
"Aging",
"Smooth",
"Nutritional supplement",
"food additive",
"Emulsifier",
"Barth syndrome",
"Apoptosis",
"Diabetic heart disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti bacterial, a cyclooxygenase2 inhibitor, a anti bacterial agent, and photochromic. | CC(Cl)Cl.CCCCCC.CCOC(C)=O | [
"anti bacterial",
"cyclooxygenase2 inhibitor",
"anti bacterial agent",
"photochromic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation that impacts diabetic heart disease and barth syndrome. The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts tangier disease, aging, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Barth syndrome",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Aging",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, fat storage, and inflammatory that has an effect on cancer and impacts both atherosclerosis and pancreatitis. The molecule is a energy source that impacts both obesity and cardiovascular disease. The molecule is a nutrient and a membrane stabilizer, impacting both thyroxine treatment and metabolic syndrome. | CCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Energy storage",
"Cancer",
"Atherosclerosis",
"Pancreatitis",
"Fat storage",
"inflammatory",
"Obesity",
"Cardiovascular disease",
"Energy source",
"Thyroxine treatment",
"Metabolic syndrome",
"nutrient",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cysteine protease inhibitor, a protease inhibitor, and a cathepsin s inhibitor, and it impacts metabolic disease treatment. | Cn1c(=O)n(C2CCN(Cc3[nH]c(-c4ccc(C(F)(F)F)cc4)nc3-c3ccccc3)CC2)c2ccccc21 | [
"cysteine protease inhibitor",
"protease inhibitor",
"cathepsin s inhibitor",
"metabolic disease treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hcv inhibitor, a anti viral compound, a ns5a inhibitor, and anti viral. | CC(C)(C)OC(=O)N1C(c2nc3ccc(-c4ccc5c(c4)CCc4[nH]c(C6CC7CC7N6C(=O)OCc6ccccc6)nc4-5)cc3[nH]2)CC2CC21 | [
"anti viral",
"hcv inhibitor",
"anti viral compound",
"ns5a inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts barth syndrome. The molecule is a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, aging, diabetic heart disease, and tangier disease. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Aging",
"Diabetic heart disease",
"Tangier disease",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | COc1c(C(C)C)cc2c3c1OC(=O)C1CCC(C)(C)C(CC2)C31 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts tangier disease, diabetic heart disease, and barth syndrome. The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure that impacts aging and non-alcoholic fatty liver disease. | CCCCC/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Apoptosis",
"Cholesterol translocation",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC/C=C\CC(O)/C=C/C=C/C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCCCCCCCCCCCCCCCCCC | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a serine protease inhibitor and a factor xa inhibitor. | COC1CC(C(=O)Nc2ccc(-n3cccc(C#N)c3=O)cc2F)N(C(=O)Nc2ccc(Cl)cc2)C1 | [
"serine protease inhibitor",
"factor xa inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, stabilizing cytochrome oxidase that impacts barth syndrome and tangier disease. The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts aging, diabetic heart disease, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Apoptosis",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts cervical cancer, atherosclerosis, ulcerative colitis, and breast cancer. | CCCCCCCC/C=C\CCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCC[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]1O | [
"Cervical cancer",
"nutrient",
"Atherosclerosis",
"Ulcerative colitis",
"Breast cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a member of the thyroxine treatment class and affects both metabolic syndrome and atherosclerosis. The molecule is a fat storage and a nutrient, impacting both cardiovascular disease and pancreatitis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCC | [
"Thyroxine treatment",
"Metabolic syndrome",
"Atherosclerosis",
"Cardiovascular disease",
"Fat storage",
"nutrient",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts barth syndrome, diabetic heart disease, and aging. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, apoptosis that impacts tangier disease and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Tangier disease",
"Apoptosis",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both metabolic syndrome and atherosclerosis. The molecule is a fat storage and a thyroxine treatment, impacting both cardiovascular disease and pancreatitis. | CCCCCC/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCCCC | [
"Metabolic syndrome",
"nutrient",
"Atherosclerosis",
"Fat storage",
"Thyroxine treatment",
"Cardiovascular disease",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a organic optoelectronic device and belongs to the organic light-emitting diode class of molecules, with the characteristic of being optoelectronic. | CC1(C)c2ccccc2-c2ccc(-c3ccc4c(c3)c3cc(-c5ccc6c(c5)C(C)(C)c5c-6ccc6oc7ccccc7c56)ccc3n4-c3ccccc3)cc21 | [
"optoelectronic",
"organic optoelectronic device",
"organic light-emitting diode"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a renin inhibitor and a ace inhibitor, belonging to the hypertension treatment class of molecules. | CC(=O)c1cnc(C(O)C(CC2CCCCC2)NC(=O)C(Cc2cnc[nH]2)NC(=O)C(CC(=O)NCCCN2CCCC2=O)Cc2c[nH]c3ccccc23)[nH]1 | [
"renin inhibitor",
"ace inhibitor",
"hypertension treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts diabetes mellitus type 1, diabetes mellitus type 2, and pick's disease. The molecule is a nutrient that impacts atherosclerosis, insulin resistance, and cardiovascular disease. | CCCCCCCC/C=C\CC/C=C/[C@@H](O)[C@H](COP(=O)([O-])OCC[N+](C)(C)C)NC(=O)CCC/C=C\C/C=C\C/C=C\CC1OC1CCCCC | [
"Diabetes mellitus type 1",
"Diabetes mellitus type 2",
"Pick's disease",
"Atherosclerosis",
"Insulin resistance",
"Cardiovascular disease",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts barth syndrome, tangier disease, and aging. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Diabetic heart disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Aging",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts diabetes mellitus type 2, parkinson's disease, non-alcoholic fatty liver disease, and alzheimer's disease. | CCCCC/C=C\C=C\C(=O)CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCc1oc(CCC)c(C)c1C)COP(=O)(O)OCCN | [
"Diabetes mellitus type 2",
"Parkinson's disease",
"Non-alcoholic fatty liver disease",
"Alzheimer's Disease",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts diabetic heart disease and barth syndrome. The molecule is a cholesterol translocation and a apoptosis that impacts tangier disease, aging, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Cholesterol translocation",
"Apoptosis",
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a faah inhibitor and a anxiety treatment. | O=C(CCCC1CCN(Cc2ccc3cccnc3n2)CC1)c1ncco1 | [
"faah inhibitor",
"anxiety treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage, nutrient, inflammatory, and energy source, impacts obesity, and is thyroxine treatment. The molecule is a energy storage that affects cancer by impacting cardiovascular disease. The molecule is a membrane stabilizer that impacts metabolic syndrome, atherosclerosis, and pancreatitis. | CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCC(C)C | [
"Fat storage",
"nutrient",
"Thyroxine treatment",
"inflammatory",
"Energy source",
"Obesity",
"Energy storage",
"Cardiovascular disease",
"Cancer",
"Metabolic syndrome",
"Membrane stabilizer",
"Atherosclerosis",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a liquid crystal display device. | CCC(C)c1ccc(O)cc1 | [
"liquid crystal display device"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a egfr inhibitor and a anti tumor. | CNCC=CC(=O)Nc1cc2c(Nc3ccc(OCCOCC(F)(F)F)c(Cl)c3)ncnc2cc1OCCOC | [
"egfr inhibitor",
"anti tumor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, inflammatory, fat storage that impacts cardiovascular disease, atherosclerosis, and obesity. The molecule is a member of the thyroxine treatment class and affects both pancreatitis and metabolic syndrome. The molecule is a energy storage, a energy source, and a membrane stabilizer, and it impacts cancer. | CC(C)CCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C | [
"Cardiovascular disease",
"Atherosclerosis",
"nutrient",
"inflammatory",
"Obesity",
"Fat storage",
"Thyroxine treatment",
"Pancreatitis",
"Metabolic syndrome",
"Energy storage",
"Cancer",
"Energy source",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts aging, tangier disease, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, apoptosis, cholesterol translocation that impacts non-alcoholic fatty liver disease and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Cholesterol translocation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti retroviral. | COc1ccc(CN2C(c3cccc([N+](=O)[O-])c3)C(C(=O)[O-])C(=O)C(C(=O)O)C2c2cccc([N+](=O)[O-])c2)cc1 | [
"anti retroviral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, tangier disease, and aging. The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis that impacts diabetic heart disease and barth syndrome. | CCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Aging",
"Diabetic heart disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, apoptosis that impacts diabetic heart disease and tangier disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Cholesterol translocation",
"Apoptosis",
"Tangier disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, inflammatory, energy source, energy storage, nutrient that impacts atherosclerosis. The molecule is a fat storage that impacts both obesity and metabolic syndrome. The molecule is a member of the thyroxine treatment class and affects cardiovascular disease, pancreatitis, and cancer. | CCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCC(C)C | [
"Membrane stabilizer",
"inflammatory",
"Energy source",
"Energy storage",
"Atherosclerosis",
"nutrient",
"Obesity",
"Metabolic syndrome",
"Fat storage",
"Cardiovascular disease",
"Thyroxine treatment",
"Pancreatitis",
"Cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is thyroxine treatment and it impacts both metabolic syndrome and cardiovascular disease. The molecule is a nutrient and a fat storage, impacting both pancreatitis and atherosclerosis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCC | [
"Metabolic syndrome",
"Cardiovascular disease",
"Thyroxine treatment",
"nutrient",
"Pancreatitis",
"Fat storage",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a hcv inhibitor and a anti viral. | C=CC1(C(F)(F)F)CC1 | [
"hcv inhibitor",
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a ec 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, cyclooxygenase inhibitor, pesticide and belongs to both the molluscicide and anti filarial classes of molecules. | C=CCCCCCCCC(=O)O | [
"molluscicide",
"EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor",
"cyclooxygenase inhibitor",
"pesticide",
"anti filarial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts breast cancer, diabetes mellitus, colorectal cancer, and cardiovascular disease. It impacts seizure, parkinson's disease, stomach cancer, and alzheimer's disease. | CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)OC[C@@H]1COP(=O)(O)O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](C/C=C\CCCC(=O)O1)[C@@H](O)CC(O)O[C@H](/C=C\[C@@H](O)CCCCC)[C@@H](O)[C@H]2O | [
"Breast cancer",
"Diabetes mellitus",
"Colorectal cancer",
"Cardiovascular disease",
"Seizure",
"Parkinson's disease",
"Stomach cancer",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts diabetic heart disease and tangier disease. The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Aging",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, apoptosis, cholesterol translocation that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts barth syndrome, aging, and tangier disease. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Barth syndrome",
"Aging",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a organic electroluminescent device and belongs to the luminescent class of molecules, with the characteristic of being electroluminescent. | CC1(C)c2ccccc2-c2cc(N(c3ccc(-c4ccc(C5CCCCC5)cc4)cc3)c3ccc4ccccc4c3-c3ccc4c5ccccc5n(-c5ccccc5)c4c3)ccc21 | [
"luminescent",
"organic electroluminescent device",
"electroluminescent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a kinase inhibitor. | CC1COC(NC(=O)c2cc(-n3ncc4cc(Nc5ccccc5Cl)cnc43)cs2)=N1 | [
"kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | COc1cc2c(c(C)c1C(=O)O)C(=O)c1c(O)cccc1C2=O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts diabetic heart disease and tangier disease. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCC(C)CC | [
"Aging",
"Barth syndrome",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hcv polymerase inhibitor. | CCCc1ccc(CNC(=O)C2CN(c3ccc(C(=O)O)c(F)c3)CCN2S(=O)(=O)c2ccc(CC)cc2)cc1 | [
"hcv polymerase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a protein kinase inhibitor, a kinase inhibitor, and a jnk inhibitor. | OCCN1CCN(CCCOc2cccc(Nc3nccc(-c4cnc(-c5cccc(OCc6ccccc6)c5)[nH]4)n3)c2)CC1 | [
"protein kinase inhibitor",
"kinase inhibitor",
"jnk inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
When heated to decomposition it emits toxic fumes of nitroxides. | CCCCNC | [
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a surfactant and a energy storage, impacting both barth syndrome and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, nutritional supplement, energy source, emulsifier, and smooth. The molecule is a membrane stabilizer, a apoptosis, and a food additive, and it impacts aging. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and tangier disease. | CCC(C)CCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | [
"surfactant",
"Barth syndrome",
"Energy storage",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Nutritional supplement",
"Smooth",
"Energy source",
"Emulsifier",
"Membrane stabilizer",
"Aging",
"Apoptosis",
"food additive",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts tangier disease. The molecule is a proton trap for oxidative phosphorylation that impacts barth syndrome, diabetic heart disease, aging, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Cholesterol translocation",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Diabetic heart disease",
"Aging",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts aging and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts diabetic heart disease, tangier disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Aging",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts tangier disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts aging and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Tangier disease",
"Apoptosis",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti viral, a anti cancer, and anti inflammatory. | CC(=O)N1CCN(S(=O)(=O)c2ccc(Oc3ccc(CN4CCC(N(C(=O)Nc5ccc(C)nc5)c5cccc(F)c5)CC4)cn3)cc2)CC1 | [
"anti viral",
"anti inflammatory",
"anti cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a protease inhibitor and belongs to the anti viral class of molecules. | CC1C(=O)N(c2nc3ccc([N+](=O)[O-])cc3s2)C2CCN(C(=O)C3CCCN3C(=O)OC(C)(C)C)C12 | [
"protease inhibitor",
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts aging and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts tangier disease, non-alcoholic fatty liver disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Aging",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a organic electroluminescent device and belongs to the electroluminescent class of molecules. | c1ccc(-c2cccc(-c3nc(-n4c5ccccc5c5c6c7ccccc7c7ccccc7c6c6ccccc6c54)nc4ccccc34)c2)cc1 | [
"electroluminescent",
"organic electroluminescent device"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, food additive, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure. The molecule is a stabilizing cytochrome oxidase, surfactant, membrane stabilizer, nutritional supplement that impacts tangier disease. The molecule is a cholesterol translocation and a energy source, impacting both aging and diabetic heart disease. The molecule is a emulsifier and a apoptosis, which impacts both non-alcoholic fatty liver disease and barth syndrome, and is characterized as smooth. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCCCC | [
"Energy storage",
"food additive",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"surfactant",
"Membrane stabilizer",
"Nutritional supplement",
"Tangier disease",
"Cholesterol translocation",
"Energy source",
"Aging",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Emulsifier",
"Apoptosis",
"Smooth",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts pancreatitis, atherosclerosis, and cardiovascular disease. The molecule is a fat storage and a nutrient, impacting both metabolic syndrome and thyroxine treatment. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@@H](COC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COC(=O)CCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Pancreatitis",
"Atherosclerosis",
"Cardiovascular disease",
"Metabolic syndrome",
"Thyroxine treatment",
"Fat storage",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a jak inhibitor. | CN(C)Cc1nsc(NC(=O)N2CC3CCCC3C2)n1 | [
"jak inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a protease inhibitor and a cathepsin inhibitor. | COc1ccc(C(=O)NC(CC(=O)O)c2ccccc2C)nc1-c1ccc(C#N)cc1 | [
"protease inhibitor",
"cathepsin inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts barth syndrome, aging, and tangier disease. The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts diabetic heart disease and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Diabetic heart disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | O=C(O)c1cc2c([nH]c3ccccc32)c(-c2ccco2)n1 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts pain treatment. | Cn1nnnc1-c1ccc2c(c1)Oc1ccccc1C2=C1CC2CCC(C1)N2 | [
"pain treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a vasoconstrictor agent, alpha-adrenergic agonist, non-narcotic analgesic, serotonergic agonist. | CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1 | [
"vasoconstrictor agent",
"alpha-adrenergic agonist",
"non-narcotic analgesic",
"serotonergic agonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti cancer class of molecules. | COc1ccc2nccc(Oc3ccc(CC(=O)O)c(OC)c3)c2n1 | [
"anti cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a angiotensin ii antagonist that impacts cardiovascular treatment. | COCCn1c(=O)[nH]c2nc(C3CCCCC3)n(Cc3ccc(-c4ccccc4-c4nn[nH]n4)cc3)c2c1=O | [
"cardiovascular treatment",
"angiotensin ii antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, apoptosis that impacts diabetic heart disease and tangier disease. The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts non-alcoholic fatty liver disease, barth syndrome, and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Barth syndrome",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory and a membrane stabilizer that impacts cancer, metabolic syndrome, obesity, and cardiovascular disease. The molecule is a thyroxine treatment, a nutrient, and a energy source. The molecule is a energy storage and a fat storage, impacting both pancreatitis and atherosclerosis. | CCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Cancer",
"inflammatory",
"Metabolic syndrome",
"Obesity",
"Cardiovascular disease",
"Membrane stabilizer",
"Thyroxine treatment",
"nutrient",
"Energy source",
"Pancreatitis",
"Energy storage",
"Atherosclerosis",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts aging, barth syndrome, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Aging",
"Barth syndrome",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, membrane stabilizer, inflammatory that impacts obesity, atherosclerosis, and metabolic syndrome. The molecule is a fat storage that impacts both cardiovascular disease and thyroxine treatment. The molecule is a energy source and a energy storage, impacting both cancer and pancreatitis. | CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCC(C)C | [
"nutrient",
"Obesity",
"Atherosclerosis",
"Membrane stabilizer",
"Metabolic syndrome",
"inflammatory",
"Cardiovascular disease",
"Fat storage",
"Thyroxine treatment",
"Cancer",
"Pancreatitis",
"Energy source",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hiv replication inhibitor and hiv integrase inhibitor, and it impacts aids treatment. | CNC(=O)C1CN2CCN(Cc3ccc(Cl)c(Cl)c3)C(=O)C2=C1O | [
"hiv replication inhibitor",
"hiv integrase inhibitor",
"AIDs treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti bacterial. | CNC(C=O)C1Cc2cccc(Cl)c2C1 | [
"anti bacterial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts diabetic heart disease. The molecule is a cholesterol translocation that impacts non-alcoholic fatty liver disease, tangier disease, barth syndrome, and aging. | CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Tangier disease",
"Barth syndrome",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease. The molecule is a cholesterol translocation that impacts barth syndrome, tangier disease, diabetic heart disease, and aging. | CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Tangier disease",
"Cholesterol translocation",
"Diabetic heart disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti viral class of molecules. | CC1=CCC(n2cc(C)c(=O)[nH]c2=O)O1 | [
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a asthma treatment and a pde4 inhibitor, belonging to the anti inflammatory class of molecules. | CC1(C)CCc2c(-c3ccoc3)nc3sc4c(NCCc5cnc[nH]5)ncnc4c3c2C1 | [
"anti inflammatory",
"asthma treatment",
"pde4 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, energy storage, nutrient, fat storage, inflammatory that impacts obesity. The molecule is a thyroxine treatment that impacts both atherosclerosis and pancreatitis. The molecule is a energy source that impacts cancer, cardiovascular disease, and metabolic syndrome. | CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCC | [
"Membrane stabilizer",
"Energy storage",
"nutrient",
"Fat storage",
"inflammatory",
"Obesity",
"Atherosclerosis",
"Thyroxine treatment",
"Pancreatitis",
"Cancer",
"Cardiovascular disease",
"Energy source",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a plasma kallikrein inhibitor. | Cc1nc(N2CC3C(C2)C3(F)F)ccc1Cc1ncc(Br)s1 | [
"plasma kallikrein inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a lrrk2 inhibitor and a cns disorder treatment. | Cc1cc2n[nH]nc2cc1C(=O)Nc1ccc2[nH]nc(-c3ccncc3)c2c1 | [
"lrrk2 inhibitor",
"cns disorder treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a mmp inhibitor and a matrix metalloproteinase inhibitor. | CCCCCCCOc1ccc(-c2ccc(C(=O)CC(CCCc3ccccc3)C(=O)O)cc2)cc1 | [
"mmp inhibitor",
"matrix metalloproteinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a aurora kinase inhibitor and is cancer treatment. | O=C(O)c1ccc(C#Cc2ncc3c(n2)-c2ccc(Cl)cc2C(c2cc(F)ccc2F)=NC3)cc1 | [
"aurora kinase inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on stomach cancer, and impacts parkinson's disease, colorectal cancer, and diabetes mellitus. It has an effect on breast cancer, and impacts alzheimer's disease, seizure, and cardiovascular disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@@H]1COC(=O)C/C=C\C[C@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](OP(=O)(O)OC1)[C@H](OP(=O)(O)O)[C@H](O)[C@@H](/C=C/[C@H](O)CCCCC)[C@H](O)C[C@@H]2O | [
"Stomach cancer",
"Parkinson's disease",
"Colorectal cancer",
"Diabetes mellitus",
"Alzheimer's Disease",
"Breast cancer",
"Seizure",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient and belongs to the thyroxine treatment class of molecules, impacting metabolic syndrome. The molecule is a fat storage that impacts cardiovascular disease, pancreatitis, and atherosclerosis. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COC(=O)CCCCCCCCC/C=C\CCCCCC)OCCCCCCCCCCCCCCCCCC | [
"nutrient",
"Metabolic syndrome",
"Thyroxine treatment",
"Cardiovascular disease",
"Pancreatitis",
"Fat storage",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti infective. | Cc1ccc(-c2sc(NC(=O)C3CCCC3)nc2C)cc1S(=O)(=O)Nc1ccc(Oc2ccc(C(F)(F)F)cc2)cc1 | [
"anti infective"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts barth syndrome, tangier disease, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts diabetic heart disease and aging. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCC | [
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a serine protease inhibitor and a type ii diabetes treatment. | N#CC1CCCN1C(=O)CNC1CC2(N3CCCS3(=O)=O)CCCC1C2 | [
"serine protease inhibitor",
"type ii diabetes treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |